Western blot analysis at 72 h indicated that treatment with either agent alone reduced the expression level of PTBP1 and modulated the cancer specific energy metabolism through switching of PKM isoform expression from PKM2 to PKM1, thus resulting in a reduction in the PKM2/PKM1 ratio (Figure 5C). Here, PTBP1 is linked to cancer.